Levels of prothrombin activation peptide F 1+2 in patients with a bleeding tendency

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Ingerslev, J ^a   Holm, M ^a   Christiansen, K ^a   Knudsen, L ^a   Negrier C ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Activation peptide; Bleeding; F1+2; Factor VII deficiency; Haemophilia; Inhibitors; Prothrombin activation peptide; Recombinant factor VIIa; rFVIIa

Indexed keywords

PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; BLEEDING TENDENCY; BLEEDING TIME; BLOOD CLOTTING; CELL DAMAGE; CLINICAL ARTICLE; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; DISEASE SUSCEPTIBILITY; FACTOR VIIA; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTHROMBIN; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0031760055     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Kernoff PBA, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham GD. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41.
2. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM, Hemophiliac Study Group. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. New Engl J Med 1980: 303:421-425.
3. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, et al. Autoplex vs. Proplex-A controlled double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62:1135-1138.
4. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlwijk JL, van Houwelingen H, van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305:717-721.
5. Glazer S, Hedner U, Falch J. Pathologic inhibitors. Management with factor VIIa. In: Anticoagulants, Physiologic, Pathologic and Pharmacologic. D. Green (editor). Boca Raton: CRC Press; 1994. pp. 131-141.
6. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegård J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (suppl 1):159-164.
7. Bruhn HD, Conard J, Mannucci PM, Monteagudo J, Pelzer H, Reverter JC, et al. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination. Thromb Haemost 1992; 68:413-417.
8. Gadducci A, Marrai R, Baicchi U, Gagetti O, Facchini V, Genazzani AR. Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gynecol Oncol 1996; 61:215-217.
9. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and post-operative state of coagulation in plasma of patients with benign and malignant colorectal disease: a preliminary study. Thromb Haemost 1996; 76:523-528.
10. Solymoss S, Bovill EG. Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Am J Clin Pathol 1996; 105:293-297.
11. Knudsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, Djurhuus C. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 1996; 84:45-54.
12. Urlesberger B, Zobel G, Zenz W, Kuttnig-Haim M, Maurer U, Reiterer F, et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Paediatr 1996; 129:264-268.
13. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993; 39:683-686.
14. Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PL, Harman C, et al. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994; 87:782-788.
15. Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, et al. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76:23-28.
16. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa independent of tissue factor: implications for the therapeutic mechanism of high dose factor VIIa in hemophilia. Blood 1994; 83:38-42.
17. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiations of coagulation. Blood 1995; 86:1794-1801.